GILD · News · 20260917N
HIV Prevention Access Pressure
GILEAD SCIENCES, INC. · 2026-09-17 · Importance 34 · Surprise 42 · In source text
Gilead expanded royalty-free voluntary licensing for investigational once-yearly lenacapavir to generic manufacturers covering 120 high-incidence, resource-limited countries, supporting manufacturing readiness and potential supply ahead of Phase 3 results and regulatory approvals. The company also agreed with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir in 14 Latin American and Caribbean countries. The initiatives broaden access to long-acting HIV prevention and could increase future volumes while affecting access economics and product mix. Lenacapavir remains investigational for prevention, with commercial availability dependent on clinical and regulatory milestones.
Key facts
- Gilead Sciences is expanding six royalty-free voluntary licensing agreements with generic manufacturers that cover 120 high-incidence, resource-limited countries to support manufacturing readiness and supply ahead of Phase 3 trial results and potential regulatory approvals for investigational once-yearly lenacapavir for HIV prevention. source
- Gilead signed a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir in Latin America and the Caribbean. source
- The PAHO-Gilead agreement could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. source
- Mercier Johanna, Chief Communications & Corporate Affairs Officer at GILEAD Sciences, sold 3,000 shares in three separate transactions between $143.69 and $145.29 per share on September 15, 2026 and, following these sales, retains 116,684 shares, representing approximately 2.5% of her previous holdings. source
- Gilead Sciences' stock rose following the announcement of expanded royalty-free licensing agreements for lenacapavir covering 120 countries, with the stock trading near 12-month highs and above its intrinsic value based on some models. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | Gilead Sciences is expanding six royalty-free voluntary licensing agreements with generic manufacturers that cover 120 high-incidence,… |
| revenue | unclear | contingent | — | Gilead signed a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir in Latin… |